MedTrace Logo

B181 Metobes-III: Weight Loss Maintenance of a New Bioactive Compound (Metobes-Long)

NCT00302263 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2006-03-14

No results posted yet for this study

Summary

To investigate the 5-hour acute effect on energy expenditure, substrate oxidation and ad libitum food intake after intake of the Metobes-compound (green tea extract, capsaicin, tyrosine, caffeine). Furthermore, to investigate if the effect of the Metobes-compound can be inhibited by blocking the β-adrenergic receptors.

The effect of the Metobes-compound will be investigated by:

1. 5-hour energy expenditure and respiratory quotient (ventilated hood).
2. 5-h change in blood pressure and heart rate
3. 5-h change in sympathetic/parasympathetic ratio.
4. Ad libitum energy intake.
5. Self-reported postprandiel appetite sensations (VAS).

Conditions

Interventions

DRUG

Metobes-compound

Sponsors & Collaborators

  • Metabolife

    collaborator INDUSTRY

  • University of Copenhagen

    lead OTHER

Principal Investigators

  • Jens Kondrup, PhD · Department of Human Nutrition, The Royal Veterinary and Agricultural University, Denmark

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-01-31
Completion
2005-04-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00302263 on ClinicalTrials.gov